GlassScriptPhysician profile
Anastasia Traband
NPI 1851686331
$4,150.51
in general payments reported to CMS, 2019-2025
25 companies · $1,073 in 2025
The $1,073 reported for 2025 was more than what 75% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $444 · 2020: $132 · 2021: $377 · 2022: $481 · 2023: $689 · 2024: $954 · 2025: $1,073.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,716.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $947.09 | 2022-2025 | Ozurdex, Durysta |
| Regeneron Healthcare Solutions, INC. | $898.47 | 2020-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $433.57 | 2019-2025 | Vabysmo |
| Allergan, INC. | $264.85 | 2020-2021 | |
| Tarsus Pharmaceuticals, INC. | $189.80 | 2025 | Xdemvy |
| Alimera Sciences, INC. | $175.34 | 2019-2023 | Iluvien, Yutiq |
| Glaukos Corporation | $175.29 | 2022-2025 | Idosetr, Istent Infinite |
| Astellas Pharma Global Development | $150.00 | 2024 | Izervay |
| Aerie Pharmaceuticals, INC. | $148.91 | 2019-2021 | |
| Astellas Pharma US INC | $119.45 | 2023-2025 | Izervay |
| Alcon Vision LLC | $83.37 | 2022-2025 | Rocklatan, Clareon, Unity |
| Bausch & Lomb Americas INC. | $82.28 | 2022-2025 | Visudyne, Xipere, Xiidra |
| Eyepoint US, INC. | $74.41 | 2022 | |
| Apellis Pharmaceuticals, INC. | $71.10 | 2023-2025 | Syfovre |
| Novartis Pharmaceuticals Corporation | $49.13 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coherus Oncology, INC. | $48.03 | 2023 | |
| Sight Sciences, INC. | $44.69 | 2021 | |
| Ani Pharmaceuticals, INC. | $44.22 | 2025 | Iluvien, Yutiq |
| Mallinckrodt Hospital Products INC. | $42.85 | 2024-2025 | Acthar |
| Genentech, INC. | $27.33 | 2023 | Vabysmo |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Amgen INC. | $17.14 | 2025 | Tepezza |
| Kala Pharmaceuticals, INC. | $17.00 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $15.97 | 2019 | |
| Spark Therapeutics, INC. | $12.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anastasia Traband listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.